Cathie Wood’s ARK sells Twist Bioscience stock, buys more Intellia

ARK Invest reshuffled ARKK holdings on September 11, selling $5.84M of Twist Bioscience, $4.02M of 10x Genomics and $4.11M of Bullish shares. The firm also sold $2.03M of Tempus AI, $0.64M of GeneDx and $0.71M of Alphabet, while adding $1.37M of Intellia Therapeutics. The activity signals continued portfolio rotation toward Intellia and away from several genomics, AI and crypto-related positions, with limited broad market implications.

Analysis

These flows are too small relative to normal turnover and the underlying companies' liquidity to establish a standalone fundamental signal; the more relevant mechanism is positioning. ARK’s disclosed activity is mechanically front-run by retail and short-term systematic accounts, so the highest-probability effect is a 1-3 day dispersion move in the smaller, less-liquid names rather than a durable rerating. That effect should be strongest in TWST, TXG and TEM, where elevated duration sensitivity leaves multiples vulnerable if oil-driven inflation continues to push real-rate expectations higher.

The second-order issue is that genomics and AI-healthcare valuations depend on financing conditions more than near-term earnings. A sustained rise in long-end yields would increase dilution risk for cash-consuming biotech platforms and pressure hospitals/labs to defer discretionary sequencing and data-platform spend, creating a weaker 6-18 month demand backdrop for TWST, TXG, TEM and WGS. NTLA is distinct: its valuation is dominated by clinical/regulatory probabilities, so incremental fund buying is not a reason to own it absent visibility on trial readouts, cash runway and safety data.

Consensus may overinterpret a high-profile manager's rebalancing as differentiated research. The cleaner signal is relative: GOOG's small reduction is immaterial against its liquidity and cash generation, while speculative life-science names remain exposed to a macro regime that rewards balance-sheet durability. This view is falsified if real yields retreat materially, biotech capital-markets issuance reopens on favorable terms, or the genomics names produce bookings/guidance upgrades that demonstrate demand resilience.

Key Decisions for Investors

• No directional trade solely on the disclosed ARK activity; monitor the next 3-5 sessions for abnormal volume and borrow tightening in TWST, TXG and TEM before treating fund-flow pressure as actionable.
• Over the next 1-3 months, consider a relative-value short basket of TWST/TXG/TEM versus XBI, sized beta-neutral, if the 10-year real yield remains elevated or rises further. Target 10-15% relative downside; cover on a 7% relative move against the position, a material decline in real yields, or company-specific bookings guidance that exceeds expectations.
• Maintain GOOG as the quality leg against speculative healthcare-duration exposure rather than reacting to the small sale: long GOOG / short equal-dollar ARKG or a selected genomics basket over 3-6 months. The thesis fails if AI-related capex materially compresses GOOG free-cash-flow guidance or if biotech funding conditions improve enough to drive sustained multiple expansion.
• Treat NTLA as a catalyst watch, not a flow-following long. Reassess only ahead of independently verifiable clinical or regulatory updates; require adequate cash runway through the next major readout and no adverse safety signal before initiating exposure.